Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lundbeck
Biotech
The GLP-like race to keep us awake and make billions doing it
Experts told Fierce that orexin mimics have much broader potential than narcolepsy and could even become the “GLPs of neuroscience.”
Darren Incorvaia
Aug 31, 2026 11:24am
EMD Serono taps in new commercial strategy head—Chutes & Ladders
Jun 26, 2026 8:30am
Vedana surfaces with $46M to develop migraine prevention therapies
Jun 17, 2026 9:48am
Lundbeck’s preventative migraine IV sees success in ph. 2
Feb 12, 2026 1:25pm
Takeda inks $1.7B AI discovery deal with Iambic Therapeutics
Feb 9, 2026 8:00am
Lundbeck ends subcutaneous migraine cohort after futility review
Apr 1, 2025 5:00am